Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 26, 2017
Reporting Period: The filing covers events occurring on September 26, 2017, and a stockholder letter dated September 27, 2017, regarding expected product sales for the quarter ending September 30, 2017.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or margin data. The only specific financial figures disclosed relate to contractual obligations under a new agreement:
- Minimum Annual Aggregate Purchases (2023): €3,625,000 (approx. $4,273,000)
- Minimum Annual Aggregate Purchases (2024): €3,825,000 (approx. $4,509,000)
- Minimum Annual Aggregate Purchases (2025): €4,000,000 (approx. $4,715,000)
The filing text does not provide a clear value for current liquidity, debt levels, or operating results.
Material Changes
The primary material change is the execution of a Fourth Amendment to the License and Supply Agreement with Medica S.p.A. on September 26, 2017. Key changes include:
- Term Extension: The agreement term was extended through December 31, 2025.
- New Purchase Obligations: The Company agreed to minimum annual purchase commitments for the years 2023, 2024, and 2025 as listed above.
- Contractual Rights: Section 7.1, which granted the Company a right of first refusal regarding a change of control of Medica or the sale of Medica products/technology, was deleted.
Guidance, Outlook, and Risks
Outlook: On September 27, 2017, the Company distributed a letter to stockholders disclosing expected product sales for the quarter ending September 30, 2017. The specific sales figures are contained in Exhibit 99.1 and are not detailed in the body of this 8-K text.
Risks and Contingencies: The deletion of the right of first refusal regarding Medica's change of control represents a shift in the Company's strategic protections. The new minimum purchase obligations create future cash outflow commitments.
Regulatory Note: The information regarding expected sales (Item 2.02 and Item 7.01) is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to liability under that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Letter to Stockholders) for the specific expected product sales figures for the quarter ending September 30, 2017.
- Examine Exhibit 10.1 (Fourth Amendment) for the complete terms of the purchase obligations and the implications of removing the right of first refusal.
- Verify the Company's ability to meet the new minimum annual purchase commitments of approximately $4.3M to $4.7M starting in 2023.
- Confirm the impact of the agreement extension on the Company's long-term supply chain stability.